312 related articles for article (PubMed ID: 27569351)
1. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Utsunomiya N; Matsumoto K; Tsunemori H; Muguruma K; Kawakita M; Kamiyama Y; Kanamaru S; Ito N; Tsukazaki H; Shirahase T; Takahashi T
Hinyokika Kiyo; 2016 Jul; 62(7):341-7. PubMed ID: 27569351
[TBL] [Abstract][Full Text] [Related]
2. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
4. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
Lee SH; Byun SS; Lee SJ; Kim KH; Lee JY
Int Urol Nephrol; 2014 Mar; 46(3):523-9. PubMed ID: 24097273
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia.
Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
Am J Mens Health; 2016 Mar; 10(2):157-63. PubMed ID: 26186951
[TBL] [Abstract][Full Text] [Related]
8. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia.
Momose H; Hosokawa Y; Kishino T; Ono T; Oyama N
Drugs Today (Barc); 2007 Feb; 43 Suppl A():1-10. PubMed ID: 17401467
[TBL] [Abstract][Full Text] [Related]
9. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
10. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
[TBL] [Abstract][Full Text] [Related]
11. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
Sakai H; Igawa T; Onita T; Furukawa M; Hakariya T; Hayashi M; Matsuya F; Shida Y; Nishimura N; Yogi Y; Tsurusaki T; Takehara K; Nomata K; Shiraishi K; Shono T; Aoki D; Kanetake H
Hinyokika Kiyo; 2011 Jan; 57(1):7-13. PubMed ID: 21304253
[TBL] [Abstract][Full Text] [Related]
13. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study.
Sakalis V; Sfiggas V; Vouros I; Salpiggidis G; Papathanasiou A; Apostolidis A
Int J Urol; 2018 Aug; 25(8):737-745. PubMed ID: 30008188
[TBL] [Abstract][Full Text] [Related]
14. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.
Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Prokofyeva A; Loparev S
Aging Male; 2018 Jun; 21(2):121-129. PubMed ID: 29113548
[TBL] [Abstract][Full Text] [Related]
15. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
[TBL] [Abstract][Full Text] [Related]
17. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
Kosugi S; Ikemoto I; Furuta A; Shimomura T; Kiyota H; Suzuki Y; Kishimoto K; Egaway S; Torii S; Shirai H; Takeuchi H; Abe K
Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):691-9. PubMed ID: 17682448
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
Ichihara K; Masumori N; Fukuta F; Tsukamoto T; Iwasawa A; Tanaka Y
J Urol; 2015 Mar; 193(3):921-6. PubMed ID: 25254938
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study.
Kwon SY; Lee KS; Yoo TK; Chung JI; Lee JY; Hong JH; Seo SI; Jung TY; Kwak C; Kang TW; Yun SJ
Urology; 2018 Jan; 111():145-150. PubMed ID: 28624553
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]